- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05079217
Safety and Immunogenicity Study of Booster Vaccination With Medium-dosage or High-dosage SARS-CoV-2 Inactivated Vaccine for Prevention of COVID-19
13 februari 2022 uppdaterad av: Sinovac Biotech Co., Ltd
A Randomized, Double-Blinded Clinical Trial to Evaluate Additional Dose of Medium-dosage or High-dosage SARS-CoV-2 Inactivated Vaccine in Healthy Individuals Previously Vaccinated With CoronaVac
This is a randomized, double-blinded, phase ⅠV clinical trial of SARS-CoV-2 inactivated vaccine manufactured by manufactured by Sinovac Research & Development Co., Ltd.
The purpose of this study is to evaluate the safety and immunogenicity of booster vaccination with high-dosage SARS-CoV-2 vaccine in populations who have received two-dose Coronavac with 2nd dose vaccinated more than 6 month.
Studieöversikt
Status
Aktiv, inte rekryterande
Betingelser
Intervention / Behandling
Detaljerad beskrivning
This study a randomized, double-blinded, phase ⅠV clinical trial of SARS-CoV-2 inactivated vaccine .The purpose of this study is to evaluate the safety and immunogenicity of booster vaccination with high-dosage SARS-CoV-2 vaccine in populations who have received two-dose Coronavac with 2nd dose vaccinated more than 6 month.A total of 1200 subjects who have received two-dose Coronavac with 2nd dose vaccinated more than 6 month will be enrolled.All of subjects will be randomly divided into two groups in a 1:1 ratio .Subjects in experimental group will receive high-dosage SARS-CoV-2 inactivated vaccine.Subjects in control group will receive medium-dosage SARS-CoV-2 inactivated vaccine .
Studietyp
Interventionell
Inskrivning (Förväntat)
1200
Fas
- Fas 4
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
Jiangsu
-
Xinqi, Jiangsu, Kina, 221400
- Xinqi City Center for Disease Control and Prevention
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
18 år och äldre (Vuxen, Äldre vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria:
- Adults aged 18-59;
- Proven legal identity;
- The subjects can understand and voluntarily sign the informed consent form and be willing to complete the study in accordance with the study plan;
- Have received two doses of inactivated SARS-CoV-2 vaccine(CoronaVac) manufactured by Sinovac Research & Development Co., Ltd at an interval of 21 to 35 days and is currently 6-8 months (180 to 240 days) after the second dose.
Exclusion Criteria:
- History of SARS-CoV-2 infection(laboratory confirmed);
- Have received three and more doses of inactivated SARS-CoV-2 vaccine;
- Severe adverse reactions, such as urticaria, dyspnea, and angioneurotic edema , occurred during the primary immunization;
- Autoimmune disease such as systemic lupus erythematosus or immunodeficiency / immunosuppression such as AIDS, post-transplant;
- Severe chronic diseases, severe cardiovascular diseases, hypertension and diabetes that cannot be controlled by drugs, liver or kidney diseases, malignant tumors, etc;
- Severe neurological disease (epilepsy, convulsions or convulsions) or mental illness;
- Diagnosed abnormal blood coagulation function (eg, lack of blood coagulation factors, blood coagulopathy, abnormal platelets) or obvious bruising or blood coagulation;
- Immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids(excluding allergic rhinitis corticosteroid spray therapy, acute noncomplicated dermatitis superficial corticosteroid therapy) in the past 6 months;
- History of alcohol or drug abuse;
- Receipt of blood products within in the past 3 months;
- Receipt of other investigational drugs in the past 30 days;
- Receipt of attenuated live vaccines in the past 14 days;
- Acute diseases or acute exacerbation of chronic diseases within 7 days prior to booster vaccination;
- Axillary temperature >37.0°C;
- Already pregnant or are breastfeeding, planning to get pregnant within 1months (according to subjects' self-report and urine pregnancy test results);
- Participated in other clinical trials prior to enrollment and during the follow-up period, or planned to participate in other clinical trials during the clinical trial period;
- According to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial.
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Förebyggande
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Experimental Group
600 participants will receive one dose of booster vaccination with high-dosage inactivated SARS-CoV-2 vaccine .
|
SARS-CoV-2 Inactivated Vaccine 1200SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
Andra namn:
|
Aktiv komparator: Control Group
600 participants will receive one dose of booster vaccination with medium-dosage inactivated SARS-CoV-2 vaccine .
|
SARS-CoV-2 Inactivated Vaccine 600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Immunogenicity index-GMT of neutralizing antibodies(CZ02 strain)
Tidsram: Day 28 after booster vaccination
|
GMT of neutralizing antibodies(CZ02 strain) 28 days after booster vaccination.
|
Day 28 after booster vaccination
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Immunogenicity index-seropositive rate of neutralizing antibodies(CZ02 strain)
Tidsram: Day 28 after booster vaccination
|
The seropositive rate of neutralizing antibodies(CZ02 strain) 28 days after booster vaccination
|
Day 28 after booster vaccination
|
Immunogenicity index-seroconversion rate of neutralizing antibodies(CZ02 strain)
Tidsram: Day 28 after booster vaccination
|
The seroconversion rate of neutralizing antibodies(CZ02 strain) 28 days after booster vaccination
|
Day 28 after booster vaccination
|
Immunogenicity index-GMI of neutralizing antibodies(CZ02 strain)
Tidsram: Day 28 after booster vaccination
|
GMI of neutralizing antibodies(CZ02 strain) 28 days after booster vaccination
|
Day 28 after booster vaccination
|
Immunogenicity index-seropositive rate of neutralizing antibodies(Delta Strain)
Tidsram: Day 28 after booster vaccination
|
The seropositive rate of neutralizing antibodies(Delta Strain) 28 days after booster vaccination
|
Day 28 after booster vaccination
|
Immunogenicity index-seroconversion rate of neutralizing antibodies(Delta Strain)
Tidsram: Day 28 after booster vaccination
|
The seroconversion rate of neutralizing antibodies(Delta Strain) 28 days after booster vaccination
|
Day 28 after booster vaccination
|
Immunogenicity index-GMI of neutralizing antibodies(Delta Strain)
Tidsram: Day 28 after booster vaccination
|
GMI of neutralizing antibodies(Delta Strain) 28 days after booster vaccination
|
Day 28 after booster vaccination
|
Immunogenicity index-seroconversion rate of neutralizing antibodies(Omicron Strain)
Tidsram: Day 28 after booster vaccination
|
The seroconversion rate of neutralizing antibodies(Omicron Strain) 28 days after booster vaccination
|
Day 28 after booster vaccination
|
Immunogenicity index-seropositive rate of neutralizing antibodies(Omicron Strain)
Tidsram: Day 28 after booster vaccination
|
The seropositive rate of neutralizing antibodies(Omicron Strain) 28 days after booster vaccination
|
Day 28 after booster vaccination
|
Immunogenicity index-GMI of neutralizing antibodies(Omicron Strain)
Tidsram: Day 28 after booster vaccination
|
GMI of neutralizing antibodies(Omicron Strain) 28 days after booster vaccination
|
Day 28 after booster vaccination
|
Immunogenicity index-GMT of neutralizing antibodies(Omicron Strain)
Tidsram: Day 28 after booster vaccination
|
GMT of neutralizing antibodies(Omicron Strain) 28 days after booster vaccination
|
Day 28 after booster vaccination
|
Immunogenicity index-GMT of neutralizing antibodies(Delta Strain)
Tidsram: Day 28 after booster vaccination
|
GMT of neutralizing antibodies(Delta Strain) 28 days after booster vaccination
|
Day 28 after booster vaccination
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Immunogenicity index-the seropositive rate of neutralizing antibodies(CZ02 strain,Delta Strain and Omicron Strain)
Tidsram: 6 months after the booster vaccination
|
The seroconversion rate of neutralizing antibodies(CZ02 strain,Delta Strain and Omicron Strain) 6 months after the booster vaccination
|
6 months after the booster vaccination
|
Immunogenicity index-GMT of neutralizing antibodies(CZ02 strain,Delta Strain and Omicron Strain)
Tidsram: 6 months after the booster vaccination
|
GMI of neutralizing antibodies(CZ02 strain,Delta Strain and Omicron Strain) 6 months after the booster vaccination
|
6 months after the booster vaccination
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Utredare
- Huvudutredare: Hongxing Pan, Master, Jiangsu Provincial Center for Disease Prevention and Control
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Faktisk)
17 december 2021
Primärt slutförande (Faktisk)
21 december 2021
Avslutad studie (Förväntat)
1 juni 2022
Studieregistreringsdatum
Först inskickad
14 oktober 2021
Först inskickad som uppfyllde QC-kriterierna
14 oktober 2021
Första postat (Faktisk)
15 oktober 2021
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
2 mars 2022
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
13 februari 2022
Senast verifierad
1 oktober 2021
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- PRO-nCOV-4007
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Nej
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Covid-19
-
Yang I. PachankisAktiv, inte rekryterandeCOVID-19 luftvägsinfektion | COVID-19 stresssyndrom | Covid-19-vaccinbiverkning | Covid-19-associerad tromboembolism | COVID-19 Post-Intensive Care Syndrome | Covid-19-associerad strokeKina
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico och andra samarbetspartnersAvslutadPostakuta följder av covid-19 | Tillstånd efter covid-19 | Lång covid | Kroniskt covid-19 syndromItalien
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRekryteringCovid-19 pandemi | Covid-19 vacciner | COVID-19 virussjukdomIndonesien
-
First Affiliated Hospital Xi'an Jiaotong UniversityShangluo Central Hospital; Ankang Central Hospital; Hanzhong Central Hospital och andra samarbetspartnersRekryteringCovid-19 | Post-COVID-19 syndrom | Postakut covid-19 | Akut covid-19Kina
-
Indonesia UniversityRekryteringPost-COVID-19 syndrom | Lång covid | Tillstånd efter covid-19 | Post-COVID syndrom | Lång covid-19Indonesien
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkHar inte rekryterat ännuPost-COVID-19 syndrom | Lång covid | Lång Covid19 | Tillstånd efter covid-19 | Post-COVID syndrom | Tillstånd efter covid-19, ospecificerat | Tillstånd efter covidNederländerna
-
Endourage, LLCRekryteringLång covid | Lång Covid19 | Postakut covid-19 | Long Haul COVID | Långdistans covid-19 | Postakut covid-19 syndromFörenta staterna
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyAvslutadPost-COVID-19 syndrom | Long-COVID-19 syndromTyskland
-
Medisch Spectrum TwenteZiekenhuisgroep Twente; University of TwenteAktiv, inte rekryterande
Kliniska prövningar på High-dosage SARS-CoV-2 vaccine
-
Istituto Clinico HumanitasRekrytering
-
Kern Medical CenterAvslutadCovid-19 | Sociala bestämningsfaktorer för hälsa | Penetrerande skadaFörenta staterna
-
City of Hope Medical CenterNational Cancer Institute (NCI)RekryteringKronisk lymfatisk leukemi | Covid-19 infektionFörenta staterna
-
Sinovac Research and Development Co., Ltd.Aktiv, inte rekryterande
-
Shanghai Municipal Center for Disease Control and...China National Biotec Group Company LimitedHar inte rekryterat ännuMässling | Röda hund | Påssjuka | Vattkoppor | SARS-CoV-2-infektionKina
-
GeoVax, Inc.National Cancer Institute (NCI); City of Hope Medical CenterAktiv, inte rekryterandeCovid-19 infektionFörenta staterna
-
Livzon Pharmaceutical Group Inc.Aktiv, inte rekryterande
-
PT Bio FarmaFakultas Kedokteran Universitas Indonesia; Faculty of Medicine, Diponegoro...Avslutad
-
PT Bio FarmaNational Institute of Health Research and Development, Ministry of Health... och andra samarbetspartnersAvslutad
-
Hospitales Universitarios Virgen del RocíoAktiv, inte rekryterandeHumoral och cellulär immunitet mot SARS-COV-2-vaccin hos HIV-infekterade immunsupprimerade patienterHIV-infektion | SARS-CoV-2 RNA-vaccinSpanien